AFC-HD AMS Life Science Co., Ltd. (JP:2927)
:2927
Top Page
AFC-HD AMS Life Science Co., Ltd.
(2927)
Select Model
Select Model
Rating:64Neutral
Price Target:
¥945.00
▲(9.38% Upside)
Action:DowngradedDate:01/04/26
The score is driven by attractive valuation (low P/E and solid yield) and a supportive technical trend, but it is meaningfully constrained by financial quality risks—especially persistent negative free cash flow and above-average leverage.
Positive Factors
Revenue Growth
Consistent revenue growth indicates robust demand for the company's products, enhancing its market position and long-term sustainability.
Negative Factors
High Capital Expenditures
High capital expenditures strain cash flow, potentially limiting liquidity and financial flexibility if sustained over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates robust demand for the company's products, enhancing its market position and long-term sustainability.
Read all positive factors
AFC-HD AMS Life Science Co., Ltd. (2927) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥12.51B
Dividend Yield3.94%
Average Volume (3M)18.87K
Price to Earnings (P/E)5.9
Beta (1Y)0.45
Revenue Growth11.47%
EPS Growth29.21%
CountryJP
Employees994
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)36.70
Shares Outstanding14,559,699
10 Day Avg. Volume18,160
30 Day Avg. Volume18,870
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)0.80
Price to Sales (P/S)0.37
P/FCF Ratio-6.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AFC-HD AMS Life Science Co., Ltd. Business Overview & Revenue Model
Company Description
AFC-HD AMS Life Science Co., Ltd. operates as an original equipment manufacturer of health foods and supplements. It plans, researches, develops, and processes, as well as completes dietary supplement and cosmetics. The company offers health foods...
How the Company Makes Money
AFC-HD AMS Life Science Co., Ltd. generates revenue through the sale of its health and beauty products. The company's key revenue streams include direct sales to consumers through various retail channels, including online platforms and physical st...
AFC-HD AMS Life Science Co., Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
58
Neutral
Cash Flow
41
Neutral
| Breakdown | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 32.66B | 30.19B | 25.58B | 23.00B | 22.37B |
| Gross Profit | 10.97B | 10.49B | 9.32B | 8.58B | 6.87B |
| EBITDA | 3.80B | 3.10B | 2.59B | 2.30B | 2.86B |
| Net Income | 1.45B | 1.25B | 1.10B | 735.35M | 1.50B |
Balance Sheet | |||||
| Total Assets | 48.73B | 47.03B | 41.07B | 37.35B | 35.75B |
| Cash, Cash Equivalents and Short-Term Investments | 11.30B | 12.17B | 11.18B | 10.38B | 9.22B |
| Total Debt | 24.14B | 23.40B | 19.59B | 17.24B | 14.77B |
| Total Liabilities | 33.53B | 33.07B | 27.91B | 24.90B | 23.09B |
| Stockholders Equity | 15.08B | 13.93B | 13.11B | 12.44B | 11.92B |
Cash Flow | |||||
| Free Cash Flow | -1.75B | -1.87B | -1.07B | 534.45M | 2.09B |
| Operating Cash Flow | 1.79B | 1.54B | 865.28M | 1.49B | 2.58B |
| Investing Cash Flow | -3.33B | -2.76B | -1.95B | -1.08B | -274.97M |
| Financing Cash Flow | 666.75M | 2.23B | 1.88B | 1.16B | 2.19B |
AFC-HD AMS Life Science Co., Ltd. Technical Analysis
Neutral
864.00
Price Trends
885.38
Negative
871.75
Positive
858.50
Positive
Market Momentum
0.84
Positive
47.20
Neutral
50.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2927, the sentiment is Neutral. The current price of 864 is below the 20-day moving average (MA) of 887.90, below the 50-day MA of 885.38, and above the 200-day MA of 858.50, indicating a neutral trend. The MACD of 0.84 indicates Positive momentum. The RSI at 47.20 is Neutral, neither overbought nor oversold. The STOCH value of 50.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2927.
AFC-HD AMS Life Science Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | ¥66.70B | 8.46 | ― | 3.63% | 1.78% | 19.50% | |
70 Outperform | ¥586.21B | 11.01 | ― | 3.15% | -0.88% | -25.64% | |
70 Outperform | ¥17.67B | 48.02 | ― | ― | 7.07% | ― | |
64 Neutral | ¥12.51B | 5.91 | ― | 3.94% | 11.47% | 29.21% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | ¥41.95B | 4.13 | ― | 1.52% | 6.00% | -45.34% | |
59 Neutral | ¥36.80B | 8.05 | ― | 3.84% | 6.49% | 31.81% |
* Consumer Defensive Sector Average
JP:2927
AFC-HD AMS Life Science Co., Ltd.
883.00
74.38
9.20%
JP:1375
YUKIGUNI MAITAKE CO., LTD.
1,051.00
-65.27
-5.85%
JP:2002
Nisshin Seifun Group Inc.
2,130.50
386.02
22.13%
JP:2936
BASE FOOD Inc.
331.00
-256.00
-43.61%
JP:3139
Lacto Japan Co., Ltd.
3,675.00
918.20
33.31%
JP:4526
Riken Vitamin Co., Ltd.
2,925.00
565.97
23.99%
AFC-HD AMS Life Science Co., Ltd. Corporate Events
AFC-HD AMS Life Science Posts Higher Q1 Profits and Stronger Balance Sheet
Jan 14, 2026
AFC-HD AMS Life Science Co., Ltd. reported solid year-on-year growth for the first quarter of the fiscal year ending August 2026, with net sales rising 4.4% to ¥8,547 million and operating profit increasing 18.6% to ¥771 million. Ordinar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.